GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

As of now, AIM has obtained FDA approval to begin clinical trials for two major mRNA vaccine products: the mRNA shingles vaccine and the mRNA RSV vaccine. In just one month, AIM has leveraged its ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

Two words come to mind for Elizabeth Banks after her showdown with shingles: "Not fun." ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

Sen. Tammy Baldwin (D-Wis.) and Sen. Peter Welch (D-Vt.) will host a forum on Wednesday, March 26, to discuss how delayed NIH ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

Shingles can be an extremely painful condition and complications can be long-lasting, particularly for older people and those with weakened immune systems.

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Nodular melanoma is a type of skin cancer. It’s a dangerous form of melanoma that grows quickly. Only about 15% of all melanomas are nodular. But it causes nearly half of melanoma-related deaths.

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma, leaving the partners speculating about a possible regulatory ...